At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
AZD6765 +1 moredrug
Likely dose
AZD6765 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression
In Brief
A Phase 2 clinical trial evaluating AZD6765 and Placebo to AZD6765 for Treatment Resistant Major Depressive Disorder. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartDec 2009
Primary CompletionDec 2011
TodayJul 2026
First PostedSep 30, 2009
Enrollment StartDec 1, 2009
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.8 years ago
Interventions
AZD6765drug
Single IV infusion of 150 mg AZD6765.
Placebo to AZD6765drug
Single IV infusion of Placebo to AZD6765